Jul 2025 $20 M No. 9 $10 to $50 million 29
New Health Sciences, Inc.: Raise no. 9, Jul 2025 × Investors in this round 29 investors had bought by the notice of Aug 5, 2025: 29 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $20 M of $24 M offered; $4 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $41,250
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andrew Dunham · Executive Officer, Director · President, Chief Executive Officer, and Member of the Board of Directors Daan M. Kok · Executive Officer · Head of Business Development and Strategy Eric J. Newman · Executive Officer · Vice President, Chief Financial Officer, and Corporate Secretary Jill J. Buckley · Executive Officer · Vice President of Human Resources Laura J. Daniels · Executive Officer · Vice President of Product Development Laurel J. Omert · Executive Officer · Chief Medical Officer Robert J. Haime · Executive Officer · Vice President of Commercial Operations Eduardo Patrick Avayu · Director Geoffrey M. Crouse · Director Ismail M. Kola · Director Joseph M. Grogan · Director Paul M. Ness · Director Peter A. Testa · Director Philip M. Pead · Director Stephen A. Eckert · Director · Chairman of the Board of Directors William Patrick O'Neill · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Octavian AG · Zurich, Switzerland Sold in no state named, and outside the US Signed by Eric J. Newman, Vice President Chief Financial Officer & Corporate Secretary. Source: SEC Form D, newest notice filed Aug 5, 2025. Read the notice at the SEC .
equity SEC Nov 2024 $22 M No. 8 $10 to $50 million 51
New Health Sciences, Inc.: Raise no. 8, Nov 2024 × Investors in this round 51 investors had bought by the notice of Jul 31, 2025: 51 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $22 M of $22 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $27,188
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andrew Dunham · Executive Officer, Director · President, Chief Executive Officer, and Member of the Board of Directors Daan M. Kok · Executive Officer · Head of Business Development and Strategy Eric J. Newman · Executive Officer · Vice President, Chief Financial Officer, and Corporate Secretary Jill J. Buckley · Executive Officer · Vice President of Human Resources Laura J. Daniels · Executive Officer · Vice President of Product Development Laurel J. Omert · Executive Officer · Chief Medical Officer Robert J. Haime · Executive Officer · Vice President of Commercial Operations Eduardo Patrick Avayu · Director Geoffrey M. Crouse · Director Ismail M. Kola · Director Joseph M. Grogan · Director Paul M. Ness · Director Peter A. Testa · Director Philip M. Pead · Director Stephen A. Eckert · Director · Chairman of the Board of Directors William Patrick O'Neill · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Octavian AG · Zurich, Switzerland Sold in no state named, and outside the US Signed by Eric J. Newman, Vice President Chief Financial Officer & Corporate Secretary. Source: SEC Form D, newest notice filed Jul 31, 2025. Read the notice at the SEC .
equity SEC Dec 2023 $5 M No. 7 $2 to $10 million 10
New Health Sciences, Inc.: Raise no. 7, Dec 2023 × Investors in this round 10 investors had bought by the notice of Jan 8, 2024: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $10 M offered; $5 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andrew Dunham · Executive Officer, Director · President, Chief Executive Officer, Chief Technology Officer and Member of the Board of Directors Daan M. Kok · Executive Officer · Executive Vice President & General Manager, EMEA Eric J. Newman · Executive Officer · Vice President, Chief Financial Officer and Corporate Secretary Jill J. Buckley · Executive Officer · Vice President of Human Resources Laura J. Daniels · Executive Officer · Vice President of Product Development Laurel J. Omert · Executive Officer · Chief Medical Officer Robert J. Haime · Executive Officer · Vice President of Commercial Operations Eduardo Patrick Avayu · Director Ismail M. Kola · Director Michael David Testa · Director Paul M. Ness · Director Richard A. Perle · Director Stephen A. Eckert · Director · Chairman of the Board of Directors William Patrick O'Neill · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Eric J. Newman, Vice President Chief Financial Officer & Corporate Secretary. Source: SEC Form D, newest notice filed Jan 8, 2024. Read the notice at the SEC .
equity SEC Jun 2023 $11 M No. 6 $10 to $50 million 20
New Health Sciences, Inc.: Raise no. 6, Jun 2023 × Investors in this round 20 investors had bought by the notice of Nov 8, 2023: 20 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $11 M of $11 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $400,000
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks finders' fees as estimates
The company Corporation, incorporated in Delaware People named in the notice Andrew Dunham · Executive Officer, Director · President, Chief Executive Officer, Chief Technology Officer and Member of the Board of Directors Daan M. Kok · Executive Officer · Executive Vice President & General Manager, EMEA Eric Newman · Executive Officer · Vice President, Chief Financial Officer and Corporate Secretary Jill Buckley · Executive Officer · Vice President of Human Resources Laura Daniels · Executive Officer · Vice President of Product Development Laurel Omert · Executive Officer · Chief Medical Officer Robert Haime · Executive Officer · Vice President of Commercial Operations Eduardo Patrick Avayu · Director Ismail M. Kola · Director Michael David Testa · Director Paul M. Ness · Director Richard A. Perle · Director Stephen A. Eckert · Director · Chairman of the Board of Directors William Patrick O'Neill · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Sonenshine & Company LLC (CRD 104357) · New York, New York Sold in AL, CA, CO, CT, DE, FL, GA, IL, MA, MD, ME, MN, MO, NH, NV, NY, OH, PA, TX, VA, WA, and outside the US Remarks in the notice On fees: “Sonenshine & Co. is entitled to certain finders fees for certain investors.”Signed by Eric Newman, Vice President Chief Financial Officer & Corporate Secretary. Source: SEC Form D, newest notice filed Nov 8, 2023. Read the notice at the SEC .
equity, options SEC Jul 2022 $13 M No. 5 $10 to $50 million 38
New Health Sciences, Inc.: Raise no. 5, Jul 2022 × Investors in this round 38 investors had bought by the notice of Feb 7, 2023: 38 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $13 M of $15 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $1,125,000
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks finders' fees as estimates
The company Corporation, incorporated in Delaware People named in the notice Alex A. Marichal · Executive Officer · Vice President of Marketing Andrew A. Dunham · Executive Officer · Vice President and Chief Technology Officer Daan M. Kok · Executive Officer · Executive Vice President & General Manager, EMEA Eric A. Newman · Executive Officer · Vice President, Chief Financial Officer and Corporate Secretary Jill A. Buckley · Executive Officer · Vice President of Human Resources Kimberly M. Dorsch · Executive Officer · Vice President, Clinical Affairs Laura A. Daniels · Executive Officer · Vice President of Product Development Laurel A. Omert · Executive Officer · Chief Medical Officer Martin A. Cannon · Executive Officer, Director · President, Chief Executive Officer and Member of the Board of Directors Robert A. Haime · Executive Officer · Vice President of Commercial Operations Eduardo Patrick Avayu · Director Guy A. Cogan · Director Ismail M. Kola · Director Michael David Testa · Director Paul M. Ness · Director Richard A. Perle · Director Stephen A. Eckert · Director William Patrick O'Neill · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Sonenshine & Company LLC (CRD 104357) · New York, New York Sold in AL, CA, CT, DE, GA, IL, MA, ME, NH, NY, OH, PA, TX, VA, and outside the US Remarks in the notice On fees: “Sonenshine & Co. is entitled to certain finders fees for certain investors.”Signed by Martin A. Cannon, President, Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Feb 7, 2023. Read the notice at the SEC .
equity SEC Aug 2019 $40 M No. 4 $10 to $50 million 39
New Health Sciences, Inc.: Raise no. 4, Aug 2019 × Investors in this round 39 investors had bought by the notice of Oct 15, 2021: 39 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $40 M of $59 M offered; $20 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $1,125,000
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks finders' fees as estimates
The company Corporation, incorporated in Delaware People named in the notice Alex Patrick Marichal · Executive Officer · Vice President of Marketing Andrew Patrick Dunham · Executive Officer · Vice President and Chief Scientific Officer Eric Patrick Newman · Executive Officer · Vice President and Chief Financial Officer Jill Patrick Buckley · Executive Officer · Vice President of Human Resources Laura Patrick Daniels · Executive Officer · Vice President of Product Development Laurel Patrick Omert · Executive Officer · Chief Medical Officer Martin A. Cannon · Executive Officer, Director · President, Chief Executive Officer and member of the Board of Directors Robert Patrick Haime · Executive Officer · Vice President of Commercial Operations Eduardo Patrick Avayu · Director Guy A. Cogan · Director Michael David Testa · Director Paul M. Ness · Director Richard A. Perle · Director Stephen A. Eckert · Director William Patrick O'Neill · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Sonenshine & Company LLC (CRD 104357) · New York, New York Sold in all US states, and outside the US Remarks in the notice On fees: “Sonenshine & Co. is entitled to certain finders fees for certain investors.”Signed by Martin A. Cannon, President, Chief Executive Officer and Director. Source: SEC Form D and 2 amendments, newest notice filed Oct 15, 2021. Read the notice at the SEC .
equity SEC Feb 2018 $9 M No. 3 $2 to $10 million 6
New Health Sciences, Inc.: Raise no. 3, Feb 2018 × Investors in this round 6 investors had bought by the notice of Oct 26, 2018: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $9 M of $16 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eric David Newman · Executive Officer · Vice President and Chief Financial Officer Joseph David Barrett · Executive Officer · General Counsel and Secretary Martin A. Cannon · Executive Officer, Director · President, Chief Executive Officer and member of the Board of Directors David A. Herman · Director Guy A. Cogan · Director Michael David Testa · Director Richard A. Perle · Director Stephen A. Eckert · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Martin A. Cannon, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 26, 2018. Read the notice at the SEC .
debt, options SEC Oct 2017 $3 M No. 2 $2 to $10 million 6
New Health Sciences, Inc.: Raise no. 2, Oct 2017 × Investors in this round 6 investors had bought by the notice of Dec 19, 2017: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $5 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Joseph David Barrett · Executive Officer · General Counsel and Secretary Lynn David Mallett · Executive Officer · Vice President and Chief Financial Officer Martin A. Cannon · Executive Officer, Director · President, Chief Executive Officer and member of the Board of Directors David A. Herman · Director Guy A. Cogan · Director Michael David Testa · Director Richard A. Perle · Director Stephen A. Eckert · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Martin A. Cannon, President, Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Dec 19, 2017. Read the notice at the SEC .
equity SEC Jul 2011 $12 M No. 1 $10 to $50 million 3
New Health Sciences, Inc.: Raise no. 1, Jul 2011 × Investors in this round 3 investors had bought by the notice of Dec 16, 2013: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $12 M of $18 M offered; $5 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Martin A. Cannon · Executive Officer, Director · Member of Board of Directors, President and Chief Executive Officer Michael A. Bavonese · Executive Officer · Director of Finance and Administration and Corporate Secretary David A. Herman · Director David A. Testa · Director Guy A. Cogan · Director Richard A. Perle · Director Steve A. Eckert · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Martin A. Cannon, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 16, 2013. Read the notice at the SEC .
equity, options SEC